Effect of abrocitinib and dupilumab on eosinophil levels in patients with moderate‐to‐severe atopic dermatitis

Background Eosinophilia is common in patients with atopic dermatitis (AD). Abrocitinib, an oral Janus kinase-1 inhibitor and dupilumab, anti–interleukin-4 receptor-α antibody, are approved for moderate-to-severe AD. Dupilumab has been associated transient eosinophilia. Objectives To assess the effect of abrocitinib dupilumab on eosinophils from phase 3 JADE COMPARE (NCT03720470) EXTEND (NCT03422822) trials. Methods In COMPARE, received once-daily (200/100 mg), placebo or subcutaneous (300 mg, biweekly) background topical therapy. ongoing long-term study (Data cutoff: April 22, 2020), dupilumab-treated mg) The proportion eosinophilia hypereosinophilia, association clinical efficacy was assessed. Adverse events (AEs) were also Results Of 837 58 (25.7%), 47 (19.7%) 51 (21.1%) had at baseline 200 100 mg groups, respectively. At Week 16, decreased (9.3%) (19.0%) but not (21.5%); no cases hypereosinophilia observed compared (1.9%) (2.3%). Decreases median eosinophil counts greater (difference, −100/mm3) (−70/mm3) than (+25/mm3) (+30/mm3) 16. Similar trends comorbid asthma allergic rhinitis. to 12 who switched EXTEND. Decreased correlated positively improvements AD severity, itch sleep loss. No eosinophilia-associated AEs occurred. Conclusions Abrocitinib Resolution efficacy.